E237 - (CME) TD Realities: Patient Quality of Life with Tardive Dyskinesia
Release Date: 10/23/2024
NEI Podcast
Join Dr. Andy Cutler and Dr. Cynthia Bulik as they discuss the challenges of diagnosing and treating binge eating disorder (BED). They explore the genetics, neurobiology, and clinical course of BED that inform treatment decisions, and examine how advances in genetic research and emerging pharmacological options may improve outcomes for individuals with BED. Cynthia Bulik, PhD, FAED is a Distinguished Professor of Eating Disorders in the Department of Psychiatry, a Professor of Nutrition in the Gillings School of Global Public Health and the Founding Director of the Center of...
info_outlineNEI Podcast
Join Dr. Andy Cutler and Dr. Carla Sharp as they discuss the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also covers recent updates to the APA’s BPD guidelines. Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean...
info_outlineNEI Podcast
In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care. Target Audience: This activity has been developed for the healthcare team or individual prescriber...
info_outlineNEI Podcast
Join Dr. Andy Cutler as he speaks with Dr. Anita Clayton about one of the most common yet least discussed side effects of psychotropic medications—sexual dysfunction. They explore the different aspects of sexual dysfunction that may arise as a side effect, how to distinguish these from symptoms of psychiatric or medical disorders, and how to collaborate with patients to effectively address this challenging issue. Anita H. Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences, and Professor of Clinical Obstetrics & Gynecology at...
info_outlineNEI Podcast
Join Dr. Andy Cutler as he speaks with Dr. Christine Moutier about the unintended effects of the FDA boxed warnings on antidepressant use in pediatric patients—specifically, the underdiagnosis and undertreatment of depression. Their conversation highlights the importance of effectively treating depression to reduce suicide across the lifespan. Christine Yu Moutier, MD is a leading psychiatrist and the Chief Medical Officer at the American Foundation for Suicide Prevention (AFSP). Since joining AFSP in 2013, Dr. Moutier has led a nationwide movement combining scientific research and...
info_outlineNEI Podcast
Join Dr. Andy Cutler as he talks with Dr. Jeffrey Strawn about how clinicians can determine the appropriate scenarios for benzodiazepine deprescribing, best practices for benzodiazepine tapering, and how to balance patient preferences to ensure best outcomes. Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC,...
info_outlineNEI Podcast
In this episode of our special pediatric psychopharmacology series, Dr. Jeffrey Strawn and Dr. Katherine Dahlsgaard review how psychiatric prescribers can incorporate cognitive behavioral therapy (CBT) practices into medication checks with pediatric patients who have anxiety disorders. Specifically, they discuss the importance of using exposures to reduce avoidance behaviors that are characteristic of and feed anxiety disorders. Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati...
info_outlineNEI Podcast
Join Dr. Andy Cutler as he talks with Dr. Descartes Li about the facts and fiction of electroconvulsive therapy (ECT). They discuss the efficacy and potential side effects of ECT, as well as the importance of educating patients and clinicians on ECT in order to overcome stigma associated with this life-saving treatment. Descartes Li, MD is a psychiatrist who specializes in caring for patients with bipolar disorder and patients receiving electroconvulsive therapy. He directs the UCSF Bipolar Disorders Program and the UCSF Electroconvulsive Therapy Program. Dr. Li's research...
info_outlineNEI Podcast
In this special episode, we present highlights from the PsychopharmaStahlogy Show, hosted by Dr. Andy Cutler and featuring Dr. Stephen Stahl. Join us as we share clips from the most popular episodes of the series, showcasing some of the most though-provoking moments. (01:13) Clip from (16:16) Clip from (29:31) Clip from (42:50) Clip from Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: Interested in...
info_outlineNEI Podcast
In this episode of our special pediatric psychopharmacology series, Dr. Jeffrey Strawn and Dr. Robyn Thom discuss the situations in which psychotropic medications are appropriate for children with autism spectrum disorder. They also explore strategies for managing side effects of these medications, including cases involving polypharmacy in this population. Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical...
info_outlineIn this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.
Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.
Learning Objectives: After completing this educational activity, you should be better able to:
- Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients
- Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD
- Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life

Estimated Time to Complete: 1 hour
Released: October 23, 2024* Expiration: October 22, 2027
*NEI maintains a record of participation for six (6) years.
- Physician: ACCME AMA PRA Category 1 Credits™
- NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
- Nurse: ANCC contact hours
- NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour
- Nurse Practitioner: ACCME AMA PRA Category 1 Credit™
- American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
- The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics.
- Pharmacy: ACPE application-based contact hours
- This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU).
- The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period.
- Physician Associate/Assistant: AAPA Category 1 CME credits
NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation.
- Psychology: APA CE credits
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
- Social Work: ASWB-ACE CE credits
- As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits.
- Non-Physician Member of the Healthcare Team: Certificate of Participation
- NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity.
- Interprofessional Continuing Education: IPCE credit for learning and change
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.
Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships.
Faculty Author / Presenter
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Malvern, PA
Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda
Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences
Faculty Author / Presenter
Leslie Citrome, MD, MPH
Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY
Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda
Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva
Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options)
The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O’Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.
Contact Us: For questions regarding this educational activity, or to cancel your account, please email [email protected].
Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.